PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing ...

Nuclear fusion. People on Mars. Artificial general intelligence. These are just some of the advances that could come by the ...

Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today ...

PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of ...

The AI bubble debate rages as markets head into 2026. We asked eight top investors what side they're on and where they would ...

This year, hype around AI really exploded, and so did concerns about AI’s environmental footprint. We also saw some ...

Two phase III studies of setrusumab, Orbit and Cosmic, for treating brittle bones have failed and left the developers floundering on Wall Street. Neither of Ultragenyx Pharmaceutical Inc. and Mereo ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for ...

The Dow Jones Industrial Average and other major stock indexes ended Tuesday's session slightly lower, sticking in negative ...

For Section 337 investigations before the U.S. International Trade Commission (ITC), 2025 was a year of contrasts.

U.S. policy, China’s strategic rise, blockbuster deals and AI dominated South Korea’s biotechnology industry this year, with U.S. tariffs and the Biosecure Act’s hitch onto 2026 legislation serving as ...